Nanoparticle-based Modulation of CD4 T Cell Effector and Helper Functions Enhances Adoptive Immunotherapy

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Oct 14

PMID 36241639

Authors

Ariel Isser

Aliyah B Silver

Hawley C Pruitt

Michal Mass

Emma H Elias

Gohta Aihara

Si-Sim Kang

Niklas Bachmann

Ying-Yu Chen

Elissa K Leonard

Joan G Bieler

Worarat Chaisawangwong

Joseph Choy

Sydney R Shannon

Sharon Gerecht

Jeffrey S Weber

Jamie B Spangler

Jonathan P Schneck

Affiliations

Soon will be listed here.

Abstract

Helper (CD4) T cells perform direct therapeutic functions and augment responses of cells such as cytotoxic (CD8) T cells against a wide variety of diseases and pathogens. Nevertheless, inefficient synthetic technologies for expansion of antigen-specific CD4 T cells hinders consistency and scalability of CD4 T cell-based therapies, and complicates mechanistic studies. Here we describe a nanoparticle platform for ex vivo CD4 T cell culture that mimics antigen presenting cells (APC) through display of major histocompatibility class II (MHC II) molecules. When combined with soluble co-stimulation signals, MHC II artificial APCs (aAPCs) expand cognate murine CD4 T cells, including rare endogenous subsets, to induce potent effector functions in vitro and in vivo. Moreover, MHC II aAPCs provide help signals that enhance antitumor function of aAPC-activated CD8 T cells in a mouse tumor model. Lastly, human leukocyte antigen class II-based aAPCs expand rare subsets of functional, antigen-specific human CD4 T cells. Overall, MHC II aAPCs provide a promising approach for harnessing targeted CD4 T cell responses.

Citing Articles

Ex vivo expansion and hydrogel-mediated in vivo delivery of tissue-resident memory T cells for immunotherapy.

Li S, Yao Z, Wang H, Ecker J, Omotoso M, Lee J Sci Adv. 2024; 10(50):eadm7928.

PMID: 39671478 PMC: 11641059. DOI: 10.1126/sciadv.adm7928.

Nanomedicine for cancer patient-centered care.

Sorrentino C, Ciummo S, Fieni C, Di Carlo E MedComm (2020). 2024; 5(11):e767.

PMID: 39434967 PMC: 11491554. DOI: 10.1002/mco2.767.

Alginate-based artificial antigen presenting cells expand functional CD8 T cells with memory characteristics for adoptive cell therapy.

Omotoso M, Est-Witte S, Shannon S, Li S, Nair N, Neshat S Biomaterials. 2024; 313:122773.

PMID: 39217794 PMC: 11423771. DOI: 10.1016/j.biomaterials.2024.122773.

Biomaterials-mediated ligation of immune cell surface receptors for immunoengineering.

Cui H, Zhang L, Shi Y Immunooncol Technol. 2024; 21:100695.

PMID: 38405432 PMC: 10891334. DOI: 10.1016/j.iotech.2023.100695.

Genetically engineered CD80-pMHC-harboring extracellular vesicles for antigen-specific CD4 T-cell engagement.

Ishina I, Kurbatskaia I, Mamedov A, Shramova E, Deyev S, Nurbaeva K Front Bioeng Biotechnol. 2024; 11:1341685.

PMID: 38304104 PMC: 10833362. DOI: 10.3389/fbioe.2023.1341685.

References

Kaluza K, Thompson J, Kottke T, Flynn Gilmer H, Knutson D, Vile R . Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants. Int J Cancer. 2011; 131(4):844-54. PMC: 3903054. DOI: 10.1002/ijc.26447. View

Perica K, Bieler J, Schutz C, Varela J, Douglass J, Skora A . Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano. 2015; 9(7):6861-71. PMC: 5082131. DOI: 10.1021/acsnano.5b02829. View

Perez-Diez A, Joncker N, Choi K, Chan W, Anderson C, Lantz O . CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 2007; 109(12):5346-54. PMC: 1890845. DOI: 10.1182/blood-2006-10-051318. View

Cachot A, Bilous M, Liu Y, Li X, Saillard M, Cenerenti M . Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv. 2021; 7(9). PMC: 7909889. DOI: 10.1126/sciadv.abe3348. View

Kosmides A, Sidhom J, Fraser A, Bessell C, Schneck J . Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth. ACS Nano. 2017; 11(6):5417-5429. PMC: 8635119. DOI: 10.1021/acsnano.6b08152. View

Sha W, Nelson C, Newberry R, Kranz D, Russell J, Loh D . Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature. 1988; 335(6187):271-4. DOI: 10.1038/335271a0. View

Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J . Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015; 520(7549):692-6. PMC: 4838069. DOI: 10.1038/nature14426. View

Hunder N, Wallen H, Cao J, Hendricks D, Reilly J, Rodmyre R . Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008; 358(25):2698-703. PMC: 3277288. DOI: 10.1056/NEJMoa0800251. View

Tay R, Richardson E, Toh H . Revisiting the role of CD4 T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2020; 28(1-2):5-17. PMC: 7886651. DOI: 10.1038/s41417-020-0183-x. View

10.

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

11.

Hickey J, Isser A, Salathe S, Gee K, Hsiao M, Shaikh W . Adaptive Nanoparticle Platforms for High Throughput Expansion and Detection of Antigen-Specific T cells. Nano Lett. 2020; 20(9):6289-6298. PMC: 8008984. DOI: 10.1021/acs.nanolett.0c01511. View

12.

Wagner E, Qerqez A, Stevens C, Nguyen A, Delidakis G, Maynard J . Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display. J Biol Chem. 2019; 294(15):5790-5804. PMC: 6463697. DOI: 10.1074/jbc.RA118.007187. View

13.

Emmerich J, Mumm J, Chan I, LaFace D, Truong H, Mcclanahan T . IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 2012; 72(14):3570-81. DOI: 10.1158/0008-5472.CAN-12-0721. View

14.

Steinbrink K, Graulich E, Kubsch S, Knop J, Enk A . CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood. 2002; 99(7):2468-76. DOI: 10.1182/blood.v99.7.2468. View

15.

Oelke M, Moehrle U, Chen J, Behringer D, Cerundolo V, Lindemann A . Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res. 2000; 6(5):1997-2005. View

16.

Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M . Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature. 2022; 602(7897):503-509. PMC: 9166916. DOI: 10.1038/s41586-021-04390-6. View

17.

Ichikawa J, Yoshida T, Isser A, Laino A, Vassallo M, Woods D . Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. Clin Cancer Res. 2020; 26(13):3384-3396. PMC: 7334099. DOI: 10.1158/1078-0432.CCR-19-3487. View

18.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

19.

Moon J, Chu H, Pepper M, McSorley S, Jameson S, Kedl R . Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity. 2007; 27(2):203-13. PMC: 2200089. DOI: 10.1016/j.immuni.2007.07.007. View

20.

Day C, Seth N, Lucas M, Appel H, Gauthier L, Lauer G . Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest. 2003; 112(6):831-42. PMC: 193667. DOI: 10.1172/JCI18509. View